Immutep immutep.org


Public list: Pharma Startups (4729) Cancer Therapeutics (1129)

Immutep is a late stage privately owned biopharmaceutical company in the rapidly growing field of immuno-oncology. Immutep has been developing a number of complementary types of cancer immunotherapies based on its patented Lymphocyte Activation Gene 3 (LAG-3) technology. Its lead product IMP321 has been tested in various clinical trials to date, both alone and in combination with other therapies. Immutep holds the world-wide rights (excluding China and Taiwan) to commercialise IMP321. This inclu...Show all

Immutep is a late stage privately owned biopharmaceutical company in the rapidly growing field of immuno-oncology. Immutep has been developing a number of complementary types of cancer immunotherapies based on its patented Lymphocyte Activation Gene ...Show all

Company (Acquired)

Phone:

Fax:

2, rue Jean Rostand

Orsay, 91893
France

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Immutep $0M Oct 2, 2014

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Immutep Jobs

jobs by Indeed job
						search
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.